Medscape InDiscussion: Bladder Cancer Medscape
-
- Wetenschap
Listen to Medscape InDiscussion: Bladder Cancer, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987104). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
-
Breaking Bladder Cancer Barriers: The Promise of Gene Therapy
Drs Cheryl Lee and Stephen Boorjian share detailed insights about a model drug development partnership involving the first-in-class therapy for BCG-unresponsive non–muscle-invasive bladder cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987104). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline (2020) https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline
ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) https://clinicaltrials.gov/ct2/show/NCT02773849
Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988888/ -
How Bladder Cancer Immunostimulant N-803 May Shake Things Up
Drs Cheryl Lee and Karim Chamie talk about efforts to develop nogapendekin alfa, aka N-803, and where it may fit into the shifting treatment paradigm for non-muscle invasive bladder cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987105). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
BCG-Unresponsive High-Grade Non-Muscle-Invasive Bladder Cancer: What Does the Practicing Urologist Need to Know? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997797/
Final Clinical Results of Pivotal Trial of IL-15rαfc Superagonist N-803 With BCG in BCG-Unresponsive CIS and Papillary Non-Muscle-Invasive Bladder Cancer (NMIBC) https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4508
PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14) https://www.clincosm.com/trial/pk-sub-quilt-3032-ca-alt-803-01-16-2005-14 -
Personalized Medicine in Bladder Cancer: Inflection Point
Drs Cheryl Lee and Tom Powles talk about ctDNA and personalized medicine approaches for advanced bladder cancer as we sit at the precipice of change.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987106). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Circulating Tumor DNA: A Promising Biomarker in the Liquid Biopsy of Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217053/
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011) https://clinicaltrials.gov/ct2/show/NCT04660344
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010) https://clinicaltrials.gov/ct2/show/NCT02450331 -
Advancing Urothelial Cancer Care: Combined Therapies
Drs Cheryl Lee and Andrea Apolo discuss combination systemic therapy strategies for urothelial carcinoma, including dose de-escalation for toxicity reduction, and how ctDNA efforts are paving the way for precision medicine with the promise of biomarkers.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987107). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Systemic Treatment for Advanced Urothelial Cancer: An Update on Recent Clinical Trials and Current Treatment Options https://pubmed.ncbi.nlm.nih.gov/32668516/
PD-L1 Assessment in Urothelial Carcinoma: A Practical Approach https://pubmed.ncbi.nlm.nih.gov/31930091/
Immune Checkpoint Inhibitors in Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/35621637/
FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer https://pubmed.ncbi.nlm.nih.gov/33224141/
BCG-Unresponsive High-Grade Non-muscle Invasive Bladder Cancer: What Does the Practicing Urologist Need to Know? https://pubmed.ncbi.nlm.nih.gov/33772322/ -
Bladder Cancer SBRT: Meet Your Friendly Rad-Oncologist
Drs Cheryl Lee and Shekinah Elmore talk about how stereotactic body radiation therapy (SBRT) is being used in the treatment of oligometastatic bladder cancer — and how it's making a difference in patients' lives.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987108). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
ESTRO ACROP Guidelines for External Beam Radiotherapy of Patients With Uncomplicated Bone Metastases https://www.estro.org/About/Newsroom/Newsletter/Read-it-before-your-patients/ESTRO-ACROP-guidelines-for-external-beam-radio-(1)
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3) https://clinicaltrials.gov/ct2/show/NCT03862911
IMRT https://www.cancer.gov/publications/dictionaries/cancer-terms/def/imrt
Metastasis-directed Radiation Therapy With Consolidative Intent for Oligometastatic Urothelial Carcinoma: A Systematic Review and Meta-analysis https://pubmed.ncbi.nlm.nih.gov/35625979/
Trimodality Therapy for Bladder Cancer: Modern Management and Future Directions https://pubmed.ncbi.nlm.nih.gov/30855374/ -
How to Improve the Experience of Bladder Cancer: BCAN
Dr Cheryl Lee and Diane Zipursky Quale, Co-founder and Director of the Bladder Cancer Advocacy Network, discuss successes and ongoing efforts to level the playing field for those who experience bladder cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987109). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Bladder Cancer Advisory Network https://bcan.org/
Bladder Cancer Awareness Month 2023 https://bcan.org/bladder-cancer-awareness-month-2023/
Bladder Cancer Matters Podcast https://bcan.org/bladder-cancer-podcast/
BCAN Survivor to Survivor https://bcan.org/find-support/survivor-to-survivor/
Bladder Cancer Young Investigator Awards https://bcan.org/young-investigator-awards/
American Urological Association https://www.auanet.org/
Department of Defense Appropriations for Fiscal Year 2023 https://www.congress.gov/event/118th-congress/senate-event/LC70188/text?s=1&r=3
Bladder Cancer and Veterans: What You Need to Know https://news.va.gov/103200/bladder-cancer-and-veterans-what-you-need-to-know/#:~:text=Exposure%20risks%20for%20Veterans%3A%20Agent,chemicals%20during%20their%20military%20service.